Popular search terms:
Search Results
129 results found-
CSL Behring provides protein-based therapies for bleeding disorders, critical care, pulmonary disease, and other rare illnesses.
https://www.cslbehring.com.au/products -
CSL Behring Australia's Product Information (PI), Consumer Medicine Information (CMI), Safety Data Sheets and New Zealand Data Sheet
https://www.cslbehring.com.au/products/products-list -
In general, all patients treated with coagulation FVIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/biostate-au-pi-v3000.pdf -
The potency of C1 esterase inhibitor is expressed in International Units (IU), which are related to the current WHO Standard for C1 esterase inhibitor products.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/berinert-sc-2000-and-3000-au-pi-v500.pdf -
Not classified as hazardous according to the WHS Regulations All blood products should be treated as potentially infectious.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/sds032-albumex-4-v6.pdf -
Not classified as hazardous according to the WHS Regulations All blood products should be treated as potentially infectious.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/sds003-albumex-20-v6.pdf -
The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain infectious agents and by testing for the presence of certain viral markers.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/tetanus-immunoglobulinvf-im-au-pi-1100.pdf -
In most cases, risk factors have been identified, such as pre-existing renal insufficiency, diabetes mellitus, hypovolaemia, overweight, concomitant nephrotoxic medicinal products or age over 65.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/evogam-au-pi-1000.pdf